Salud financiera de hoja de balance de Level Bio

Salud financiera controles de criterios 4/6

Level Bio tiene un patrimonio de los accionistas total de SEK8.0M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK15.7M y SEK7.8M respectivamente.

Información clave

Ratio deuda-patrimonio

SEK 0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	SEK 1.96m
Patrimonio	SEK 4.80m
Total pasivo	SEK 9.41m
Activos totales	SEK 14.20m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?

Jun 02

Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?

Feb 10

I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With Ease

Nov 03

AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected

Aug 18

Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?

Mar 07

Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?

Nov 22

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK10.5M) de LEVBIO superan a sus pasivos a corto plazo (SEK7.2M).

Pasivo a largo plazo: Los activos a corto plazo de LEVBIO (SEK10.5M) superan a sus pasivos a largo plazo (SEK584.0K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: LEVBIO está libre de deudas.

Reducción de la deuda: LEVBIO no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: LEVBIO tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: LEVBIO tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 44.4% cada año

Salud financiera de hoja de balance de Level Bio

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

First quarter 2024 earnings released

AlphaHelix Molecular Diagnostics AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024

Full year 2023 earnings released: kr0.15 loss per share (vs kr0.035 loss in FY 2022)

AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Financial position

AlphaHelix Molecular Diagnostics AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released

AlphaHelix Molecular Diagnostics AB (publ) to Report Q2, 2023 Results on Aug 24, 2023

AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023

First quarter 2023 earnings released

Full year 2022 earnings released: kr0.035 loss per share (vs kr0.087 profit in FY 2021)

AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023

No independent directors

Third quarter 2022 earnings released

Investor sentiment improved over the past week

Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?

First quarter 2022 earnings released: EPS: kr0.022 (vs kr0.031 in 1Q 2021)

No independent directors

First quarter 2022 earnings released

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With Ease

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected

Second quarter 2021 earnings released: EPS kr0.056 (vs kr0.014 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?

New 90-day high: kr1.49

New 90-day high: kr1.44

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: kr0.82

Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?

Market pulls back on stock over the past week

New 90-day low: kr1.09

Market bids up stock over the past week

New 90-day low: kr1.20

New 90-day low - kr1.26

New 90-day low - kr1.35

Xanadu Technologies AB, Tataa Biocenter AB and Active Healthtech Nordic AB acquired a 13.17% stake in AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) from Labkompaniet AB.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera